Edgar Filing: Arbuckle Stuart A - Form 4

Arbuckle Stu Form 4	iart A										
November 05, 2018 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								OMB Number: Expires: Estimated a burden hour response	•		
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Arbuckle Stuart A			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		(Middle) RTHERN	3. Date of (Month/D 11/02/20		ransaction			Director X Officer (give below) EVP\Chief		Owner r (specify fficer	
Filed(Mon				nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
BOSTON, N		(7:-)						Person		Jorung	
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Dat (Month/Day/Year)		ned 1 Date, if	a I - Non-I 3. Transactic Code (Instr. 8) Code V	4. Securi or(A) or Di (Instr. 3,	ties Adispose 4 and (A) or	cquired d of (D)	fired, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		y Owned 7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/02/2018			М	2,155	A		48,907	D		
Common Stock	11/02/2018			S <u>(1)</u>	2,155	D	\$ 175.36	46,752	D		
Common Stock								140	I	401(k)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: Arbuckle Stuart A - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number conof Derivativ Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	e Expiration (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (I	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 91.05	11/02/2018		М	2,155	(2)	02/01/2026	Common Stock	2,155	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210			EVP\Chief Commercial Officer			
Signatures						

S

/s/ Omar White, Attorney-in-Fact

11/05/2018

Date

Signature of Reporting Person **Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- (2) The option vests in 16 quarterly installments from 02/02/2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.